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Abstract: Hookworm infection is chief among soil-transmitted helminthiases (STHs) for the chronic
morbidly inflicted. Deworming via mass drug administration (MDA) programs most often employs
single doses of benzimidazole drugs to which resistance is a constant threat. To discover new
drugs, we employ a hamster model of hookworm infection with Ancylostoma ceylanicum and use
albendazole (ABZ; 10 mg/kg orally) as the gold standard therapy. We previously showed that a
single oral 100 mg/kg dose of the cathepsin cysteine protease (CP) inhibitor, K11777, offers near cure
of infection that is associated with a 95% reduction in the parasite’s resident CP activity. We confirm
these findings here and demonstrate that odanacatib (ODN), Merck’s cathepsin K inhibitor and
post-clinical Phase III drug candidate for treatment of osteoporosis, decreases worm burden by 73%
at the same dose with a 51% reduction in the parasite’s CP activity. Unlike K11777, ODN is a modest
inhibitor of both mammalian cathepsin B and the predominant cathepsin B-like activity measureable
in hookworm extracts. ODN’s somewhat unexpected efficacy, therefore, may be due to its excellent
pharmacokinetic (PK) profile which allows for sustained plasma exposure and, possibly, sufficient
perturbation of hookworm cathepsin B activity to be detrimental to survival. Accordingly, identifying
a CP inhibitor(s) that combines the inhibition potency of K11777 and the PK attributes of ODN could
lead to a drug that is effective at a lower dose. Achieving this would potentially provide an alternative
or back-up to the current anti-hookworm drug, albendazole.
Keywords: parasite; hookworm; soil-transmitted helminth; cysteine protease; K11777; odanacatib;
Merck; anthelmintic
1. Introduction
Soil-transmitted helminthiases (STHs) caused by parasitic nematodes are associated with extreme
poverty. Of these, hookworm disease afflicts as much as 7% of the world’s population, principally in
sub-Saharan Africa, South America, and South and South-East Asia [1–4]. The disease is primarily
due to infection by Ancylostoma duodenale or Necator americanus, and is manifested particularly in the
under-nourished, causing or exacerbating iron-deficient anemia that can slow childhood physical
development and cognition [5–7]. In addition, infection can slow fetal growth, and contribute to
premature birth and maternal mortality [8–10]. Treatment and control of STHs employ periodic
de-worming with drugs. The benzimidazoles, albendazole (ABZ), mebendazole, are most often
used [11–15]. ABZ is the more effective at a single oral dose [16–20], making it suitable for mass drug
administration campaigns [12,21,22]. However, concerns over drug resistance remain, particularly
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with the recent trans-national efforts to improve access to essential drugs [23,24]. Such unease is
compounded by reports of less-than-anticipated cure rates with ABZ [25,26] (also reviewed in [27,28]),
which in one case, was neither due to poor drug quality nor issues regarding patient compliance [25].
Thus, the need for new drugs (e.g., [29,30]) remains.
As a potential new class of anthelmintic, we are investigating small molecule protease inhibitors,
specifically those that target cysteine-class cathepsins that are important to the survival of many
parasitic organisms [31,32], including flatworms and nematodes [33–36]. We employ the Golden Syrian
hamster infected with Ancylostoma ceylanicum to identify potential therapeutic agents: a single, oral
10 mg/kg dose of ABZ is our gold-standard drug regimen. Using this hamster model, we previously
demonstrated that a single, oral 100 mg/kg dose of the cathepsin cysteine protease (CP) inhibitor,
N-methyl-piperazine-phenylalanyl-homophenylalanyl-vinylsulfone-phenyl (K11777; Figure 1) [37],
provided near-cure of hookworm infection [36]. In line with the inhibitor’s mechanism of action, the
resident CP activity of worms harvested after treatment was decreased by 95% [36]. Although the
data are encouraging, the effective dose is at least ten-times greater than that of ABZ. Accordingly, we
continue to search for other CP inhibitors that either provide the necessary efficacy ‘as is’, i.e., without
further chemical modification, or act as useful starting points for further development. Here, we
describe the in vivo efficacy of Merck’s peptidomimetic, nitrile cathepsin K inhibitor, odanacatib
(ODN; Figure 1), which has completed Phase III clinical trials for treatment of post-menopausal
osteoporosis [38–40].
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Figure 1. Structures of K11777 and ODN.
2. Results and Discussion
A single, oral 100 mg/kg dose of the vinyl sulfone inhibitor, K11777, or 10 mg/kg of the current
anti-hookworm drug, ABZ, cured A. ceylanicum infection in Golden Syrian hamsters (Figure 2A).
The data are consistent with our previous findings [36]. The same 100 mg/kg dose of ODN decreased
hookworm burden by 73% (Figure 2A). A standard assay for CP activity [36,41,42] using a dipeptidyl
fluorogenic substrate was used to measure whether administration of K11777 or ODN 8 h prior to
worm recovery decreased the parasite’s specific CP activity (i.e., activity as a function of protein
concentration) relative to that measured after exposure to vehicle. For ODN and K11777, the worm
protease activities were reduced by 51% and 96%, respectively (Figure 2B).
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Figure 2. K11777 and ODN reduce Ancylostoma ceylanicum burdens in Golden Syrian hamsters and
decrease the parasite’s resident CP activity. (A) Groups of hamsters (n = 3) were infected with 75 third
stage A. ceylanicum larvae. At 18 days post-infection (DPI) hamsters were treated once orally with
K11777 (100 mg/kg) dissolved in water, or with ODN (100 mg/kg) or ABZ (10 mg/kg) dissolved in
PEG400. At 24 DPI, all hamsters were sacrificed and intestinal worms counted. Reductions in worm
burdens by ODN and K11777 were statistically significant (one-way ANOVA: p < 0.05 and p < 0.01,
respectively); (B) Hamsters (n = 1) were treated with single oral doses of K11777, ODN or the PEG400
vehicle as described in (A). Worms were harvested 8 h later and soluble extracts prepared. Specific
cysteine protease activity (relative fluorescence units/min/mg soluble extract) was measured using
the fluorogenic substrate Z-Phe-Arg-AMC. Data points are expressed as means ˘ S.D. values from a
single experiment performed in triplicate.
Based on the inhibition of the parasite’s CP activity, it seems that both inhibitors engage the
hypothesized target, namely a group of gut-a sociated cathepsin B-like enzymes [43] which are
the predominant protease activity measurable in hookworm extracts under the assay conditions
employed [36]. The smaller reduction in specific protease activity in worms exposed in vivo to ODN
(51% vs. 96% for K11777) is consistent with the inhibitor’s weaker, but still considerable, anti-parasite
efficacy (73% vs. 100% for K11777). Indeed, ODN’s efficacy is surprising given that it is 4.5 orders
of magnitude more potent against cathepsin K compared to cathepsin B (Table 1) with which the
hookworm proteases, irrespective of infecting species, share greatest homology [36,43]. In contrast,
K11777, as a non-specific inhibitor of CPs, has low nanomolar IC50 values against various mammalian
cathepsins (Table 1; reviewed in [44]).
Table 1. Inhibition of mammalian cysteine cathepsins and cruzain by CP inhibitors.
Inhibitor
Target Cathepsin and IC50 Value (nM)
CatB CatF CatK CatL CatS Cruzain
K11777 9 3 1.8 <0.2 <0.2 3.5
ODN 1034 n.t. 0.2 2995 60 n.t.
Data for K11777 from [45] and for ODN from [38] as cited in [45]. Each assay was performed twice; n.t. = not
tested; Cruzain is a cathepsin L-like protease in Trypanosoma cruzi, the etiological agent of Chagas disease [46].
Consistent with the poor inhibition of mammalian cathepsin B by ODN, we recorded modest
49.8% and 40.2% residual activities in soluble extracts of female and male hookworms, respectively,
after a 10 min incubation with 1 µM ODN (Figure 3). In contrast, after incubation with K11777 at the
same concentration, the respective hookworm cysteine protease activities were just 1.2% and 1.25% of
the DMSO control.
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Figure 3. Inhibition of hookworm cysteine protease activity by K11777 and ODN. Soluble extracts of
female (black bars) and male (grey bars) A. ceylanicum were incubated for 10 min with 1 µM inhibitor, as
described in the text. Residual cysteine protease activity was measured with the fluorogenic substrate
Z-Phe-Arg-AMC. Data were generated from two experiments each in duplicate; one experiment
is shown.
With its moderate inhibition of mammalian and hookworm cathepsins B, the question arises as to
why ODN is as effective as it is in vivo. Part of the answer may lie in its outstanding pharmacokinetics
(PK) profile which allows for once-weekly oral dosing of osteoporosis patients ([39,40]; Table 2); and
which originally prompted us to test the inhibitor. The many attractive PK features of ODN include
its low systemic clearance, long plasma half-life (T1/2) and good oral bioavailability (%F) in various
pre-clinical animal models which conceivable would provide a sustained plasma loading to generate
an anti-parasite effect (Table 2). In these same metrics, K11777, at a 20 to 50 times the dose in rats and
dogs, respectively, was noticeably poorer.
Table 2. PK parameters for ODN and K11777.
Compound Vehicle
Dose Cmax Tmax AUC0–8 T1/2 F
(mg/kg) (µM) (h) (µM¨h) (h) %
ODN (rat) 100% PEG400 5 2.2 ˘ 0.4 1.8 ˘ 1.5 36 ˘ 10 5.8 ˘ 0.8 43 ˘ 12
ODN (dog) 60% PEG400 1 3.6 8 318 64 122
ODN (monkey) Imwitor-Tween 80 (1:1) 5 0.3 ˘ 0.1 6 ˘ 2.3 4.8 ˘ 1.8 18 ˘ 4.3 18 ˘ 3.8
ODN (man) capsule 25 1 0.24 ˘ 0.052 14.2 ˘ 8.1 19.9 ˘ 4.1 96.7 ˘ 18.3 34
K11777 (mouse) water 92 2.6 0.3 3.9 0.8 n.d.
K11777 (rat) water 100 3.1 4 10.5 1.9 22
K11777 (dog) water 50 1.4 0.34 1.0 0.5 15
Data for ODN are taken from [39,40] and represent means and SD values for the rat (n = 4), dog (n = 2), monkey
(n = 4) and man (n = 6). In every case, a single oral dose was administered. Data for K11777 are from an internal
pre-IND report from SRI International (2009). Data presented are means for the mouse (n = 3), male rat (n = 3)
and dog (n = 2); n.d. = not determined; 1 Total dose (mg) administered.
If PK is a key contributor to anti-hookworm efficacy, one might improve bioactivity by identifying
small molecules that combine the nanomolar inhibition of the target cathepsin B proteases, as shown
for K11777, with the attractive PK features of ODN. This idea could be initially explored by combining
K11777 with ODN to identify potential synergistic or additive efficacy. Ideally, the combination of
improved on-target potency and PK would result in significantly lowering the dose necessary to
achieve cure, a vital goal, bearing in mind that the current drug standard, ABZ, is at least ten-fold more
effective in the hamster model. Identifying a low dose CP therapy may offer an attractive chemical
alternative or back-up to ABZ, in addition to the possibility of a combination therapy with ABZ.
Finally, within the framework of designing an improved inhibitor, possible safety concerns regarding
off-targeting of orthologous host proteases can also be addressed, mitigated by the knowledge that (i)
treatment of hookworm infection will involve acute (single-dose) therapy only and (ii) the non-specific
cathepsin inhibitor, K11777, continues to meet safety criteria as it progresses pre-clinically as a treatment
for Chagas disease.
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3. Experimental Section
3.1. Animals and Compounds
A. ceylanicum was maintained in male Golden Syrian hamsters (Mesocricetus auratus; Harlan
Sprague Dawley, Somerville, NJ, USA) as described [27,47,48]. The animal protocol supporting this
research was evaluated and approved by the University of California San Francisco’s Institutional
Animal Care and Use Committee (IACUC) with the Approval number AN098756-02B. UCSF-IACUC
derives its authority from the United States Public Health Service (PHS) Policy on Humane Care and
Use of Laboratory Animals, and the Animal Welfare Act and Regulations (AWAR). All compounds
were prepared immediately before administration to animals. ODN (MK-0822) was purchased
from Chemietek (Indianapolis, IN, USA; CT-CG001) and ABZ from Sigma Aldrich (St. Louis, MO,
USA; A4673). Prior to animal experiments ODN and ABZ were dissolved in 100% PEG400 whereas
K11777-HCl was dissolved in deionized water [33,36].
3.2. Treatment Regimens and Cysteine Protease Activity Assay
Groups of hamsters (n = 4) were infected with 75 third stage A. ceylanicum larvae by oral gavage
in 200 µL deionized water. Treatment regimens commenced at 18 days post-infection (DPI) to target
adult worms [36] using 100 mg/kg ODN or K11777, or 10 mg/kg ABZ delivered by oral gavage in
200 µL vehicle. An infected vehicle group controlling for the PEG400 vehicle was also set up. On day
24 DPI, hamsters were sacrificed and their intestinal worm burdens counted [36].
To measure the effect of compounds on worm CP activity in vivo [36], one hamster from each
of the treatment and vehicle groups was sacrificed 8 h post-treatment. Worms recovered were
washed three times in RPMI 1640 and frozen at ´80 ˝C prior to assay. Worms were thawed in
100 µL assay buffer (0.05 M sodium acetate, pH 5.5) and homogenized using RNase-free disposable
pellet pestles and microtubes (Thermo Fisher Scientific, Waltham, MA, USA) for 10 min at room
temperature. Homogenates were centrifuged at 5000 g for 10 min and the supernatants removed
for analysis. Supernatants (1–2.5 µL) were mixed with 100 µL assay buffer containing 2 mM DTT
in a black 96-well microtiter plate and left to stand at room temperature for 10 min. Then, 100 µL
of assay buffer containing 2 mM DTT and 20 µM of the dipeptidyl fluorogenic substrate, benzyloxy
carbonyl-phenylalanyl-arginyl-7-amido-4-methylcoumarin (Z-Phe-Arg-AMC) [41] was added with
mixing. Linear rates of hydrolysis were followed in a FlexStation II (Molecular Devices, Sunnyvale,
CA, USA) for 10 min. Protein concentrations of supernatants were measured using the micro-Bradford
assay (BioRad, Hercules, CA, USA).
To measure the inhibition of hookworm CP activity in vitro, the assay was prepared as described
above. K11777 and ODN (1 µL in DMSO to deliver 1 µM) were pre-incubated for 10 min with soluble
extracts of either male or female A. ceylanicum worms (harvested 24 DPI) in a volume of 100 µL assay
buffer prior to the addition of 100 µL of substrate solution.
4. Conclusions
The present data confirm the anti-hookworm efficacy of the CP inhibitor, K11777, in a small
animal model of hookworm infection and extend the finding to include a structurally unrelated CP
inhibitor, ODN. Based on differences in the CP inhibition and PK profiles between the two inhibitors,
we reason that combining the CP inhibition potency of K11777 with the PK stability of ODN should
lead to a CP inhibitor that is more effective at a lower dose thereby offering a possible drug alternative
to or back-up for ABZ.
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